ascopubs.org

ECOG score as a barrier for clinical trial eligibility in the patient population with genitourinary cancer: Is it time to adapt this criterion to real-world data?

Efficacy of systemic therapy following [177Lu] Lu-PSMA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). This is an ASCO Meeting Abstract from the 2023 ASCO Genitourinary ...
Cure Today

Whole Pelvis Radiation in Muscle-Invasive Bladder Cancer May Improve Survival

Whole pelvis radiation improves cancer-specific and overall survival in muscle-invasive bladder cancer compared to bladder-only radiation. Median cancer-specific survival was 84 months for whole ...
Cure Today

Initial Keytruda May Be Beneficial in Patients With Advanced Bladder Cancer

Keytruda shows consistent efficacy and safety in advanced bladder carcinoma patients ineligible for platinum-based chemotherapy, with varying objective response rates and survival metrics across ...
MarketWatch

ECOG-ACRIN and Caris Life Sciences unveil first findings from a multi-year collaboration to advance AI-powered multimodal tools for breast cancer recurrence risk stratification

The MarketWatch News Department was not involved in the creation of this content. New AI models integrating imaging, clinical, and molecular data from the TAILORx tissue biorepository show stronger ...
EurekAlert!

ECOG-ACRIN and Caris Life Sciences unveil first findings from a multi-year collaboration to advance AI-powered multimodal tools for breast cancer recurrence risk stratification

Researchers have reported initial findings from a public-private partnership between the ECOG-ACRIN Cancer Research Group and Caris Life Sciences to improve recurrence risk assessment in early-stage ...